We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Polyamine-free Diet to Prevent Post Surgery Hyperalgesia (PoLyDOL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00304850
Recruitment Status : Completed
First Posted : March 20, 2006
Last Update Posted : December 29, 2009
Information provided by:

Study Description
Brief Summary:
After surgery, sensitization and hyperexcitability of central nervous system result in acute and long lasting postoperative pain. It has been shown that N-methyl-D-aspartate (NMDA) receptors antagonist (such as ketamine) prevent this adverse neuroplasticity and potentiate analgesic drugs efficacy. Polyamines (putrescine, spermidine, spermine) are essential components of cells functioning and are also known as allosteric modulators of NMDA receptors. In animal studies, polyamine-free diet has confirmed these antinociceptive properties. This research aims at evaluating anti hyperalgesic properties of polyamine-free diet in women operated on breast cancer versus kétamine

Condition or disease Intervention/treatment Phase
Breast Cancer Surgery Behavioral: polyamine-free diet Drug: Ketamine or placebo Phase 2

Detailed Description:

This multicentric, single blind study will enrol 160 women (18-75 years old) operated on tumorectomy and adenectomy (T1, T2, T3, N0, N1, M0) for breast cancer. Patients will be randomly assigned in a 2x2 factorial plan : Group 1 = control (n = 40) ; group 2 = ketamine group administered during and 48 hours after a standardized anesthesia (n = 40) ; group 3 = polyamine-free diet, 1 week and 72 hours after surgery (n = 40) ; group 4 : ketamine + polyamine-free diet (n = 40).

The amount of morphine for the 24 first postoperative hours will be compared between each group as well as pain score, allodynia (Von Frey filaments) and hyperalgesia (algometer). Chronic pain occurrence (post-mastectomy pain syndrome) will be evaluated at 3 and 6 months using adequate questionnaire ( analgesic scale). Diet observance will be controlled preoperatively by a dosage of polyamines in circulating red cells blood.

Polyamines deprivation and ketamine ability to reduce postoperative pain will be compared (isobolographic method). Anti-hyperalgesic properties of ketamine have already been demonstrated in urologic, orthopaedic and abdominal surgery. In case of additive or synergistic effect of a polyamine deprivation such a strategic could be helpful to achieve better postoperative rehabilitation in reducing chronic pain after surgery.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy of a Polyamine-free Diet Associated or Not With Ketamine on Early and Late Hyperalgesia After Breast Cancer Surgery
Study Start Date : March 2006
Primary Completion Date : April 2009
Study Completion Date : May 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: R+ / K+ Behavioral: polyamine-free diet
Polyamine-free diet in the 7 days befor surgery
Drug: Ketamine or placebo
Peroperative and post operative (48h) ketamine injection
Experimental: R+ / K- Behavioral: polyamine-free diet
Polyamine-free diet in the 7 days befor surgery
Drug: Ketamine or placebo
Peroperative and post operative (48h) ketamine injection
Experimental: R- / K+ Drug: Ketamine or placebo
Peroperative and post operative (48h) ketamine injection
Placebo Comparator: R- /K- Drug: Ketamine or placebo
Peroperative and post operative (48h) ketamine injection

Outcome Measures

Primary Outcome Measures :
  1. Morphine requirement [ Time Frame: for the 24 postoperative hours ]

Secondary Outcome Measures :
  1. Pain intensity for the 4 days (and possibly at 7th day if the patient is still hospitalized) after surgery [ Time Frame: 4 days ]
  2. Allodynia measurements [ Time Frame: inclusion, 1, 2, 4 and 7 ddays after surgery ]
  3. Hyperesthesia measurements [ Time Frame: inclusion, 1, 2, 4 and 7 ddays after surgery ]
  4. Chronic pain incidence [ Time Frame: 3 and 6 months ]
  5. Late allodynia and/or hyperesthesia [ Time Frame: 6 months ]
  6. safety of treatment [ Time Frame: Along each patient folow-up ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Breast cancer (T1, T2, T3, N0, N1, M0)
  • Age : 18 - 75
  • Asa 1-3
  • left or right tumorectomy with complete lymphadenectomy
  • left or right complete mastectomy with complete lymphadenectomy
  • complete lymphadenectomy within one week following simple tumorectomy
  • informed consent signed

Exclusion Criteria:

  • inflammatory tumor requiring pre-operative radiotherapy
  • previous history of total mastectomy or partial contralateral mastectomy
  • chronic inflammatory disease treated by corticoids or NSAI
  • chronic analgesic treatment
  • anti-arrhythmic or anti-epileptic treatments
  • morphinic treatment during the 7 days before surgery
  • excessive alcohol consumption or addiction
  • ketamine or neomycin contra-indication
  • severe cardiovascular disease
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00304850

CLCC-Institut Bergonie, service d'anesthésie réanimation, 229 cours de l'Argonne
Bordeaux, France, 33000
département d'anesthésie-réanimation 3, hôpital Pellegrin
Bordeaux, France, 33076
CLCC Alexis Vautrin
Nancy, France, 54511
APHParis Hôpital Pitié Salpétrière - Dépt. d'anesthésie réanimation
Paris, France, 75013
CLCC Réné Huguenin de Saint Cloud
Saint Cloud, France, 92210
Sponsors and Collaborators
University Hospital, Bordeaux
Ministry of Health, France
Insurance CNP foundation
Principal Investigator: Pierre MAURETTE, Pr DAR 3 -Pellegrin hospital-33076 Bordeaux - France
Study Chair: Genevieve CHENE, Pr University hospital - 33076 Bordeaux - France
More Information

Responsible Party: Jean-Pierre LEROY / Clinical Research and Innovation Director, University Hospital, Bordeaux
ClinicalTrials.gov Identifier: NCT00304850     History of Changes
Other Study ID Numbers: 9258-03
First Posted: March 20, 2006    Key Record Dates
Last Update Posted: December 29, 2009
Last Verified: December 2009

Keywords provided by University Hospital, Bordeaux:
breast cancer
post operative pain

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Somatosensory Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action